A detailed history of New York State Common Retirement Fund transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 769,504 shares of HALO stock, worth $36.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
769,504
Previous 957,019 19.59%
Holding current value
$36.6 Million
Previous $50.1 Million 12.1%
% of portfolio
0.06%
Previous 0.07%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$51.3 - $64.42 $9.62 Million - $12.1 Million
-187,515 Reduced 19.59%
769,504 $44 Million
Q2 2024

Jul 31, 2024

BUY
$37.81 - $52.4 $1.48 Million - $2.06 Million
39,260 Added 4.28%
957,019 $50.1 Million
Q1 2024

May 07, 2024

SELL
$33.68 - $41.95 $1.06 Million - $1.32 Million
-31,565 Reduced 3.32%
917,759 $37.3 Million
Q4 2023

Feb 01, 2024

SELL
$33.32 - $42.1 $688,891 - $870,417
-20,675 Reduced 2.13%
949,324 $35.1 Million
Q3 2023

Nov 07, 2023

BUY
$36.46 - $44.03 $751,513 - $907,546
20,612 Added 2.17%
969,999 $37.1 Million
Q2 2023

Aug 07, 2023

BUY
$30.28 - $38.74 $3.67 Million - $4.69 Million
121,137 Added 14.63%
949,387 $34.2 Million
Q1 2023

May 02, 2023

BUY
$32.86 - $55.7 $925,304 - $1.57 Million
28,159 Added 3.52%
828,250 $31.6 Million
Q4 2022

Jan 30, 2023

SELL
$40.06 - $59.44 $6.31 Million - $9.36 Million
-157,420 Reduced 16.44%
800,091 $45.5 Million
Q3 2022

Nov 08, 2022

SELL
$38.53 - $51.78 $565,851 - $760,441
-14,686 Reduced 1.51%
957,511 $37.9 Million
Q2 2022

Aug 04, 2022

SELL
$37.35 - $48.3 $3.84 Million - $4.96 Million
-102,780 Reduced 9.56%
972,197 $42.8 Million
Q1 2022

May 05, 2022

SELL
$31.97 - $41.06 $5.9 Million - $7.57 Million
-184,473 Reduced 14.65%
1,074,977 $42.9 Million
Q4 2021

Feb 02, 2022

SELL
$31.82 - $40.75 $15.6 Million - $20 Million
-489,859 Reduced 28.0%
1,259,450 $50.6 Million
Q3 2021

Nov 02, 2021

BUY
$38.47 - $46.42 $5.15 Million - $6.22 Million
133,986 Added 8.29%
1,749,309 $71.2 Million
Q2 2021

Aug 02, 2021

SELL
$38.84 - $51.31 $2.44 Million - $3.22 Million
-62,815 Reduced 3.74%
1,615,323 $73.4 Million
Q1 2021

May 11, 2021

BUY
$39.51 - $51.45 $3.19 Million - $4.15 Million
80,756 Added 5.06%
1,678,138 $70 Million
Q4 2020

Feb 08, 2021

SELL
$25.81 - $43.62 $1.66 Million - $2.8 Million
-64,274 Reduced 3.87%
1,597,382 $68.2 Million
Q2 2020

Aug 07, 2020

BUY
$16.25 - $26.81 $2 Million - $3.3 Million
123,157 Added 8.01%
1,661,656 $44.5 Million
Q1 2020

May 06, 2020

BUY
$13.9 - $21.83 $9.18 Million - $14.4 Million
660,480 Added 75.22%
1,538,499 $27.7 Million
Q4 2019

Feb 05, 2020

SELL
$14.93 - $19.53 $2.26 Million - $2.96 Million
-151,424 Reduced 14.71%
878,019 $15.6 Million
Q3 2019

Nov 07, 2019

BUY
$15.2 - $17.69 $1.86 Million - $2.16 Million
122,090 Added 13.46%
1,029,443 $16 Million
Q2 2019

Aug 09, 2019

SELL
$14.75 - $17.26 $1.05 Million - $1.23 Million
-71,096 Reduced 7.27%
907,353 $15.6 Million
Q1 2019

May 08, 2019

SELL
$13.94 - $17.58 $970,293 - $1.22 Million
-69,605 Reduced 6.64%
978,449 $15.8 Million
Q4 2018

Feb 08, 2019

BUY
$13.33 - $18.66 $390,355 - $546,439
29,284 Added 2.87%
1,048,054 $15.3 Million
Q3 2018

Nov 07, 2018

BUY
$16.68 - $18.41 $1.7 Million - $1.88 Million
101,886 Added 11.11%
1,018,770 $18.5 Million
Q2 2018

Aug 10, 2018

BUY
$16.87 - $20.3 $649,292 - $781,306
38,488 Added 4.38%
916,884 $15.5 Million
Q1 2018

May 10, 2018

BUY
$17.06 - $21.2 $554,808 - $689,445
32,521 Added 3.84%
878,396 $17.2 Million
Q4 2017

Feb 13, 2018

BUY
$16.75 - $20.8 $93,649 - $116,292
5,591 Added 0.67%
845,875 $17.1 Million
Q3 2017

Nov 06, 2017

BUY
$11.76 - $17.4 $1.06 Million - $1.57 Million
90,243 Added 12.03%
840,284 $14.6 Million
Q2 2017

Aug 11, 2017

BUY
N/A
750,041
750,041 $9.62 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.